These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 15083199

  • 1. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
    Verschraagen M, Boven E, Torun E, Erkelens CA, Hausheer FH, van der Vijgh WJ.
    Br J Cancer; 2004 Apr 19; 90(8):1654-9. PubMed ID: 15083199
    [Abstract] [Full Text] [Related]

  • 2. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
    Verschraagen M, Boven E, Torun E, Hausheer FH, Bast A, van der Vijgh WJ.
    Biochem Pharmacol; 2004 Aug 01; 68(3):493-502. PubMed ID: 15242815
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
    Hausheer FH, Shanmugarajah D, Leverett BD, Chen X, Huang Q, Kochat H, Petluru PN, Parker AR.
    Cancer Chemother Pharmacol; 2010 Apr 01; 65(5):941-51. PubMed ID: 19714332
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
    Pendyala L, Schwartz G, Smith P, Zdanowicz J, Murphy M, Hausheer F.
    Cancer Chemother Pharmacol; 2003 May 01; 51(5):376-84. PubMed ID: 12682786
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
    Boven E, Westerman M, van Groeningen CJ, Verschraagen M, Ruijter R, Zegers I, van der Vijgh WJ, Giaccone G.
    Br J Cancer; 2005 May 09; 92(9):1636-43. PubMed ID: 15841080
    [Abstract] [Full Text] [Related]

  • 9. Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer.
    Masuda N, Negoro S, Hausheer F, Nakagawa K, Matsui K, Kudoh S, Takeda K, Yamamoto N, Yoshimura N, Ohashi Y, Fukuoka M.
    Cancer Chemother Pharmacol; 2011 Mar 09; 67(3):533-42. PubMed ID: 20473611
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
    Verschraagen M, Zwiers TH, Torun E, Donker MG, Reinhoud NJ, Van der Vijgh WJ.
    J Pharm Sci; 2003 May 09; 92(5):1040-50. PubMed ID: 12712424
    [Abstract] [Full Text] [Related]

  • 11. The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
    Verschraagen M, Kedde MA, Hausheer FH, Van Der Vijgh WJ.
    Cancer Chemother Pharmacol; 2003 Jun 09; 51(6):499-504. PubMed ID: 12715205
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.
    Parker AR, Petluru PN, Wu M, Zhao M, Kochat H, Hausheer FH.
    Mol Cancer Ther; 2010 Sep 09; 9(9):2558-67. PubMed ID: 20807779
    [Abstract] [Full Text] [Related]

  • 14. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.
    Hausheer FH, Parker AR, Petluru PN, Jair KW, Chen S, Huang Q, Chen X, Ayala PY, Shanmugarajah D, Kochat H.
    Cancer Chemother Pharmacol; 2011 Feb 09; 67(2):381-91. PubMed ID: 20440617
    [Abstract] [Full Text] [Related]

  • 15. Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.
    Shanmugarajah D, Ding D, Huang Q, Chen X, Kochat H, Petluru PN, Ayala PY, Parker AR, Hausheer FH.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr 01; 877(10):857-66. PubMed ID: 19278906
    [Abstract] [Full Text] [Related]

  • 16. Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
    Verschraagen M, Zwiers TH, de Koning PE, Welink J, van der Vijgh WJ.
    J Chromatogr B Biomed Sci Appl; 2001 Apr 05; 753(2):293-302. PubMed ID: 11334343
    [Abstract] [Full Text] [Related]

  • 17. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
    Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM.
    Semin Oncol; 1998 Oct 05; 25(5):584-99. PubMed ID: 9783598
    [Abstract] [Full Text] [Related]

  • 18. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
    Kangarloo SB, Gangopadhyay SB, Syme RM, Wolff JE, Glück S.
    Med Oncol; 2004 Oct 05; 21(1):9-20. PubMed ID: 15034209
    [Abstract] [Full Text] [Related]

  • 19. Mesna does not reduce cisplatin induced nephrotoxicity in the rat.
    Millar BC, Siddik ZH, Millar JL, Jinks S.
    Cancer Chemother Pharmacol; 1985 Oct 05; 15(3):307-9. PubMed ID: 3931929
    [Abstract] [Full Text] [Related]

  • 20. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
    DeWoskin RS, Riviere JE.
    Toxicol Appl Pharmacol; 1992 Feb 05; 112(2):182-9. PubMed ID: 1311464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.